The risks and benefits of yoga for patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis

• Published in: Clinical rehabilitation 2019-12, Vol.33 (12), p.1847-1862
• Main Authors: Cramer, Holger, Haller, Heidemarie, Klose, Petra, Ward, Lesley, Chung, Vincent CH, Lauche, Romy
• Format: Article
• Language: English
• Subjects: Bias; Chronic obstructive pulmonary disease; Clinical trials; Critical incidents; Dyspnea; Evidence-based medicine; Exercise; Humans; Intervention; Meta-analysis; Pulmonary Disease, Chronic Obstructive - complications; Pulmonary Disease, Chronic Obstructive - physiopathology; Pulmonary Disease, Chronic Obstructive - therapy; Quality of Life; Respiratory therapy; Risk Assessment; Systematic review; Yoga
• ISSN: 0269-2155; 1477-0873
• DOI: 10.1177/0269215519860551

Objectives: To determine the effectiveness and safety of yoga interventions on disease symptoms, quality of life and function in patients diagnosed with chronic obstructive pulmonary disease (COPD). Data sources: Medline/PubMed, Scopus, and CENTRAL (Cochrane Central Register of Controlled Trials) were searched through 6 June 2019. Review methods: Randomized controlled trials assessing the effects of yoga on quality of life, dyspnea, exercise capacity, and pulmonary function (FEV1) in patients with COPD were included. Safety was defined as secondary outcome. Mean differences (MD) and standardized mean differences (SMD) with 95% confidence intervals (CIs) were computed. Risk of bias was assessed using the Cochrane tool. Results: Eleven randomized controlled trials with a total of 586 patients were included. Meta-analysis revealed evidence for effects of yoga compared to no treatment on quality of life on the COPD Assessment Test (MD = 3.81; 95% CI = 0.97 to 6.65; P = 0.009, I2 = 70%), exercise capacity assessed by the 6-minute walk test (MD = 25.53 m; 95% CI = 12.16 m to 38.90 m; P = 0.001, I2 = 0%), and pulmonary function assessed by FEV1 predicted (MD  = 3.95%; 95% CI = 2.74% to 5.17%; P